Case #27 – Mac Degen in 2010

The Dawn of Pharmaco-Genetics for AMD Case Update

Supplement Formulations for Age-Related Macular Degeneration (AMD) Jerry Rapp, PhD Eye doctors should be aware of two as yet unresolved issues concerning the PreserVision supplement formulation designed to slow the progression of AMD. The first issue is the amount of zinc (Zn++) being ingested on a daily basis. AREDS2 investigators, concerned that the 80

The Dawn of Pharmaco-Genetics for AMD Case Update2021-07-20T05:16:35+00:00

Mac Degen in 2010 – Page 62 of 62

References Umeda S, Suzuki MT, Okamoto H, Ono F, Mizota A, Terao K, Yoshikawa Y,Tanaka Y, Iwata T. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). The FASEB Journal express article 10.1096/fj.04-3525fje. 2005 Wang JJ, Foran S, Smith W, Mitchell

Mac Degen in 2010 – Page 62 of 622021-03-03T20:56:06+00:00

Mac Degen in 2010 – Page 60 of 62

Jerome Sherman, OD, FAAO Jerome Sherman, O.D., is perhaps optometry's most prolific writer, publishing over 650 clinical articles, research manuscripts, book chapters and two CDs. He is senior author of three books that were published in 2007, and has delivered over three thousand lectures both nationally and internationally. He has served as a contributing

Mac Degen in 2010 – Page 60 of 622021-03-03T20:58:30+00:00

Mac Degen in 2010 – Page 58 of 62

Comments and Conclusions AMD is the leading cause of blindness in patients over 60 in the US.1 One study has shown that patients with large drusen in the posterior pole are five times more likely to develop AMD within the next five years compared to a normal individual.2 If any drusen present are a

Mac Degen in 2010 – Page 58 of 622021-03-03T20:58:47+00:00

Mac Degen in 2010 – Page 57 of 62

Summary of Clinical Studies - AMD & Low Macular Pigment Delcourt et. al. (POLA Study) (Inv. Ophth. and Visual Science: 2006) • Patients with high plasma levels of Zeaxanthin had a 93% reduction of AMD. Gale et. al. (Ophthalmology and Visual Science: 2003) • Low levels of plasma Zeaxanthin correlated with significantly higher

Mac Degen in 2010 – Page 57 of 622021-03-03T20:58:57+00:00

Mac Degen in 2010 – Page 56 of 62

Macular Pigment Following Supplement of All Three Carotenoids (MOST Study) Results: There was a significant increase in serum concentrations of MZ and L after two weeks of supplementation (p < 0.05). Four subjects (one normal and three AMD) who had an atypical MPOD spatial profile at baseline had the more typical MPOD spatial

Mac Degen in 2010 – Page 56 of 622021-03-03T20:59:05+00:00

Mac Degen in 2010 – Page 55 of 62

Macular Pigment Following Supplement of All Three Carotenoids (MOST Study) Purpose: At the macula, the carotenoids meso-zeaxanthin (MZ), lutein (L), and zeaxanthin (Z) are collectively referred to as macular pigment (MP). This study was designed to measure serum and macular responses to a macular carotenoid formulation. Materials and Methods: Ten subjects were recruited

Mac Degen in 2010 – Page 55 of 622021-03-03T20:59:13+00:00

Mac Degen in 2010 – Page 54 of 62

Estimating MP with Heterochromatic Flicker Photometry The HFP technique is based to the fact that MP acts as a filter which effects the sensitivity to different wavelengths. It absorbs blue light more than green. Two superimposed lights alternately going on and off will appear to flicker unless they are at the same

Mac Degen in 2010 – Page 54 of 622021-03-03T20:59:20+00:00